

Listing by Classification (Continued)

Class 4: This class includes therapeutic medications that would be expected to have less potential to affect performance than those in Class 3.

Drug Substance	Trade Name(s)	Drug Class	Penalty Class
Etanercept	Enbrel	4	B
Ethotoin	Peganone	4	B
Ethoxzolamide	Cardrase, Ethamide	4	C
Ethylaminobenzoate (Benzocaine)	Semets, etc.	4	C
Felodipine	Plendil	4	B
Fexofenadine	Allegra	4	C
Firocoxib		4	C
Flecainide	Idalon	4	B
Floctafenine	Idalon, Idarac	4	B
Fludrocortisone	Alforone, etc.	4	C
Flumethasone	Flucort, etc.	4	C
Flumethiazide	Ademol	4	B
Flunarizine	Sibelium	4	B
Flunisolide	Bronilide, etc.	4	C
Flunixin	Banamine	4	C*
Fluocinolone	Synalar	4	C
Fluocinonide	Licon, Lidex	4	C
Fluorometholone	FML	4	C
Fluoroprednisolone		4	B
Fluprednisolone	Alphadrol	4	C
Flurandrenolide	Cordan	4	C
Fluticasone	Flixonase, Flutide	4	C
Glycopyrrolate	Robinul	4	C
Guaifenesin (glycerol guaiacolate)	Gecolate	4	C
Halcinonide	Halog	4	C
Halobetasol	Ultravate	4	C
Hexocyclium	Tral	4	B
Hydrochlorothiazide	Hydrodiuril	4	B
Hydrocortisone (Cortisol)	Cortef, etc.	4	C
Hydroflumethiazide	Saluron	4	B
Ibuprofen	Motrin, Advil, Nurpin, etc.	4	C
Infliximab	Remicade	4	B
Isoflupredone	Predief 2x	4	C
Isometheptene	Octin, Octon	4	B
Isopropamide	Darbid	4	B
Isosuprine	Vasodilan	4	D
Isradipine	DynaCirc	4	B
Ketoprofen	Orudis	4	C*
Letosteine	Viscotol, Visiotal	4	B
Loratidine	Claritin	4	C
Meclofenamic acid	Arquel	4	C

Drug Substance	Trade Name(s)	Drug Class	Penalty Class
Medrysone	Medriusar, etc.	4	C
Meloxicam	Mobic	4	B
Mephensin	Tolserol	4	B
Meralluride	Mercuhydrin	4	B
Merbaphen	Novasural	4	B
Mercaptopimerin	Thiomerin	4	B
Mercumatinin	Cumertilin	4	B
Mersalyl	Salyrgan	4	B
Metaxalone	Skelaxin	4	B
Methazolamide	Naptazane	4	C
Methocarbamol	Robaxin	4	C
Methotrexate	Folex, Nexate, etc.	4	B
Methscopolamine	Pamine	4	B
Methsuximide	Celontin	4	B
Methylclothiazide	Enduron	4	B
Methylergonovine	Methergine	4	C
Methylprednisolone	Medrol	4	C
Methysergide	Sansert	4	B
Metiamide		4	B
Metoclopramide	Reglan	4	C
Mexiletine	Mexitil	4	C
Milrinone		4	B
Mometasone	Elocon	4	C
Montelukast	Singulair	4	C
Naphazoline	Privine	4	B
Naproxen	Equiproxen, Naprosyn	4	C
Nicardipine	Cardine	4	B
Nifedipine	Procardia	4	B
Nimodipine	Nemotop	4	B
Orphenadrine	Norfex	4	B
Oxaprozin	Daypro, Deflam	4	B
Oxymetazoline	Afrin	4	B
Oxyphenbutazone	Tandearil	4	C
Oxyphencyclimine	Daricon	4	B
Oxyphenonium	Antrenyl	4	B
Paranethasone	Haldrone	4	C
Pentoxifylline	Trental, Vazofrin	4	D
Phenacemide	Phenurone	4	B
Phensuximide	Milontin	4	B
Phenylbutazone		4	C*
Phenytotin	Dilantin	4	B
Piroxicam	Feldene	4	B

Listing by Classification (Continued)

Class 4: This class includes therapeutic medications that would be expected to have less potential to affect performance than those in Class 3.

Drug Substance	Trade Name(s)	Drug Class	Penalty Class
Polythiazide	Renese	4	B
Pramoxine	Tronothaine	4	C
Prednisolone	Delta-Cortef, etc.	4	C
Prednisone	Meticorten, etc.	4	C
Probenecid		4	C
Procainamide	Pronestyl	4	B
Propafenone	Rythmol	4	B
Proparacaine	Ophthaine	4	C
Propylhexedrine	Benzedrex	4	B
Quinidine	Quinidex, Quinicardine	4	B
Salicylamide		4	C
Salicylate		4	C
Scopolamine	Triptone	4	C
Spironolactone	Aldactone	4	B
Sulfasalazine	Azulfidine, Azaline	4	C
Terfenadine	Seldane, Triludan	4	C
Tetrahydrozoline	Tyzine	4	B
Theobromine		4	B
Thiosalicylate		4	B
Thiophenamil	Trocinat	4	B
Tocainide	Tonocard	4	B
Tranexamic acid		4	B
Triamcinolone	Vetalog, etc.	4	C
Triamterene	Dyrenium	4	C
Trichlormethiazide	Naqua, Naquasone	4	B
Tridihexethyl	Pathilon	4	C
Trimeprazine	Temaril	4	B
Vedaprofen		4	B
Verapamil	Calan, Isoptin	4	B
Xylometazoline	Otrivin	4	B
Zafirlukast	Accolate	4	C
Zeranol	Ralgro	4	C
Zileuton	Zyflo	4	C

*See Recommended Penalty Section of Document

Listing by Classification (Continued)

Class 5: This class includes those therapeutic medications for which concentration limits have been established by the racing jurisdictions as well as certain miscellaneous agents and other medications as determined by the regulatory bodies.

Drug Substance	Trade Name(s)	Drug Class	Penalty Class
Acenocoumarol		5	C
Anisindione		5	D
Cimetidine	Tagamet	5	D
Cromolyn	Intal	5	D
Dicumarol	Dicumarol	5	C
Diphenadione		5	C
Esomeprazole	Nexium	5	D
Famotidine	Gaster, etc.	5	D
Lansoprazole		5	D
Mesalamine	Asacol	5	C
Misoprostol	Cytotec	5	D
Nedocromil	Tilade	5	D
Nizatidine	Axid	5	C
Olsalazine	Dipentum	5	C
Omeprazole	Prilosec, Losec	5	D
Pantoprazole	Protonix	5	D
Phenindione	Hedulin	5	D
Phenprocoumon	Liquamar	5	D
Pirenzepine	Gastrozepin	5	C
Polyethylene glycol		5	D
Rabeprazole	Aciphex	5	D
Ranitidine	Zantac	5	D
Warfarin	Coumadin, Coufarin	5	D

Non-Classified Substances

Substances that are considered to have no effect on the physiology of a racing animal except to improve nutrition or treat or prevent infections or parasite infestations, are not classified. These Substances normally include antimicrobials, antiparasitic drugs, and nutrients such as vitamins. Examples of such substances include the following:

Sulfonamides and trimethoprim

Antibiotics:

Penicillins
 Cephalosporins
 Chloramphenicol
 Aminoglycosides
 Tetracyclines
 Nitrofurans
 Metronidazole

Anthelmintics:

Avermectins
 Benzimidazoles
 Piperazines
 Pyrantel

Antifungals
 Vitamins

A, D, E, K, B vitamins
 Vitamin C

Bufotenine

1. Note: Bufotenine is not commercially available in any form.
2. Note: Bufotenine is a metabolite of 5-methoxy-N,N-dimethyltryptamine, found in reed canary grass (and potentially other food source plants). It may be found in the urine of horses eating this grass (and potentially other plant foods), and has been reported as a positive finding. Findings of bufotenine in equine urine should not be considered for regulatory action.

NOTE: Dimethylsulphone (MSM) has been removed from the classification document and its status is "Do Not Report".

Recommended Penalty and Model Rule

The following are recommended penalties for violations due to the presence of a drug carrying a Category “A” penalty and for violations of ARCI-011-015 and ARCI-025-015: Prohibited Practices:

1 st Offense	2 nd LIFETIME offense in any jurisdiction	3 rd LIFETIME offense in any jurisdiction
<ul style="list-style-type: none"> Minimum one-year suspension absent mitigating circumstances. The presence of aggravating factors could be used to impose a maximum of a three-year suspension <p style="text-align: center;">AND</p> <ul style="list-style-type: none"> Minimum fine of \$10,000 or 10% of total purse (greater of the two) absent mitigating circumstances. The presence of aggravating factors could be used to impose a maximum of \$25,000 or 25% of purse (greater of the two). <p style="text-align: center;">AND</p> <ul style="list-style-type: none"> May be referred to the Commission for any further action deemed necessary by the Commission. 	<ul style="list-style-type: none"> Minimum three-year suspension absent mitigating circumstances. The presence of aggravating factors could be used to impose a maximum of license revocation with no reapplication for a three-year period. <p style="text-align: center;">AND</p> <ul style="list-style-type: none"> Minimum fine of \$25,000 or 25% of total purse (greater of the two) absent mitigating circumstances. The presence of aggravating factors could be used to impose a maximum of \$50,000 or 50% purse (greater of the two). <p style="text-align: center;">AND</p> <ul style="list-style-type: none"> May be referred to the Commission for any further action deemed necessary by the Commission. 	<ul style="list-style-type: none"> Minimum five-year suspension absent mitigating circumstances. The presence of aggravating factors could be used to impose a maximum of license revocation with no reapplication for a five-year period. <p style="text-align: center;">AND</p> <ul style="list-style-type: none"> Minimum fine of \$50,000 or 50% of total purse (greater of the two) absent mitigating circumstances. The presence of aggravating factors could be used to impose a maximum of \$100,000 or 100% purse (greater of the two). <p style="text-align: center;">AND</p> <ul style="list-style-type: none"> May be referred to the Commission for any further action deemed necessary by the Commission.
1 st Offense	2 nd LIFETIME offense in owner's stable any jurisdiction	3 rd LIFETIME offense in owner's stable in any jurisdiction
<ul style="list-style-type: none"> Disqualification and loss of purse <p style="text-align: center;">AND</p> <ul style="list-style-type: none"> Horse shall be placed on the Veterinarian's List for 90 days and must pass a commission-approved examination before becoming eligible to be entered. 	<ul style="list-style-type: none"> Disqualification and loss of purse <p style="text-align: center;">AND</p> <ul style="list-style-type: none"> Horse shall be placed on the Veterinarian's List for 120 days and must pass a commission-approved examination before becoming eligible to be entered. 	<ul style="list-style-type: none"> Disqualification, loss of purse and \$50,000 fine <p style="text-align: center;">AND</p> <ul style="list-style-type: none"> Horse shall be placed on the Veterinarian's List for 180 days and must pass a commission-approved examination before becoming eligible to be entered. <p style="text-align: center;">AND</p> <ul style="list-style-type: none"> Referral to the Commission with a recommendation of a suspension for a minimum of 90 days.

Recommended Penalty and Model Rule (Continued)

The following are recommended penalties for violations due to the presence of a drug carrying Category “B” penalty, for the presence of more than one NSAID in a plasma/serum sample, subject to the provisions set forth in ARCI-011-020(E) and ARCI-025-020(E) and for violations of the established levels for total carbon dioxide:

1st Offense	2nd offense (365-day period) in any jurisdiction	3rd offense (365-day period) in any jurisdiction
<ul style="list-style-type: none"> Minimum 15-day suspension absent mitigating circumstances. The presence of aggravating factors could be used to impose a maximum of a 60-day suspension <p style="text-align: center;">AND</p> <ul style="list-style-type: none"> Minimum fine of \$500 absent mitigating circumstances. The presence of aggravating factors could be used to impose a maximum fine of \$1,000. 	<ul style="list-style-type: none"> Minimum 30-day suspension absent mitigating circumstances. The presence of aggravating factors could be used to impose a maximum of a 180-day suspension <p style="text-align: center;">AND</p> <ul style="list-style-type: none"> Minimum fine of \$1,000 absent mitigating circumstances. The presence of aggravating factors could be used to impose a maximum fine of \$2,500. 	<ul style="list-style-type: none"> Minimum 60-day suspension absent mitigating circumstances. The presence of aggravating factors could be used to impose a maximum of a one-year suspension. Minimum fine of \$2,500 absent mitigating circumstances. The presence of aggravating factors could be used to impose a maximum of \$5,000 or 5% purse (greater of the two). May be referred to the Commission for any further action deemed necessary by the Commission. <p style="text-align: center;">AND</p>
1st Offense	2nd offense (365-day period) in owner's stable any jurisdiction	3rd offense (365-day period) in owner's stable in any jurisdiction
<ul style="list-style-type: none"> Disqualification and loss of purse [in the absence of mitigating circumstances]* <p style="text-align: center;">AND</p> <ul style="list-style-type: none"> Horse must pass a commission-approved examination before becoming eligible to be entered. 	<ul style="list-style-type: none"> Disqualification and loss of purse [in the absence of mitigating circumstances]* <p style="text-align: center;">AND</p> <ul style="list-style-type: none"> Horse must pass a commission-approved examination before becoming eligible to be entered. 	<ul style="list-style-type: none"> Disqualification, loss of purse, and in the absence of mitigating circumstances a \$5,000 fine.* <p style="text-align: center;">AND</p> <ul style="list-style-type: none"> Horse shall be placed on the Veterinarian's List for 45 days and must pass a commission-approved examination before becoming eligible to be entered.

Recommended Penalty and Model Rule (Continued)

The following are recommended penalties for violations due to the presence of a drug carrying a Category "C" penalty and overages for permitted NSAIDs and furosemide: *(All concentrations are for measurements in serum or plasma.)*

LICENSED TRAINER	<p>Phenylbutazone (>5.0 mcg/ml) Flunixin (>100 ng/ml) Ketoprofen (>50 ng/ml) and CLASS C Veterinary</p>	<p>Phenylbutazone (>5.0 mcg/ml) Flunixin (>100 ng/ml) Ketoprofen (>50 ng/ml) and CLASS C Veterinary</p>	<p>Phenylbutazone (>5.0 mcg/ml) Flunixin (>100 ng/ml) Ketoprofen (>50 ng/ml) and CLASS C Veterinary</p>
1 st Offense (365-day period) in any jurisdiction	Minimum of a written warning to maximum fine of \$500	Minimum of a written warning to maximum fine of \$500	Minimum fine of \$1,000 absent mitigating circumstances
2 nd Offense (365-day period) in any jurisdiction	Minimum of a written warning to maximum fine of \$750	Minimum of a written warning to maximum fine of \$750	Minimum fine of \$1,500 and 15-day suspension absent mitigating circumstances
3 rd Offense (365-day period) in any jurisdiction	Minimum fine of \$500 to a maximum fine of \$1,000	Minimum fine of \$500 to a maximum fine of \$1,000	Minimum fine of \$2,500 and 30-day suspension absent mitigating circumstances
LICENSED OWNER	<p>Phenylbutazone (>5.0 mcg/ml) Flunixin (>100 ng/ml) Ketoprofen (>50 ng/ml) and CLASS C Veterinary</p>	<p>Phenylbutazone (>5.0 mcg/ml) Flunixin (>100 ng/ml) Ketoprofen (>50 ng/ml) and CLASS C Veterinary</p>	<p>Phenylbutazone (>5.0 mcg/ml) Flunixin (>100 ng/ml) Ketoprofen (>50 ng/ml) and CLASS C Veterinary</p>
1 st Offense (365-day period) in any jurisdiction	Horse may be required to pass commission-approved examination before being eligible to run	Horse may be required to pass commission-approved examination before being eligible to run	Loss of purse. Horse must pass commission-approved examination before being eligible to run
2 nd Offense (365-day period) in any jurisdiction	Horse may be required to pass commission-approved examination before being eligible to run	Horse may be required to pass commission-approved examination before being eligible to run	Loss of purse. If same horse, placed on veterinarian's list for 45 days, must pass commission-approved examination before being eligible to run
3 rd Offense (365-day period) in any jurisdiction	Disqualification and loss of purse. Horse must pass commission-approved examination before being eligible to run	Disqualification and loss of purse. Horse must pass commission-approved examination before being eligible to run	Loss of purse. Minimum \$5,000 fine. If same horse, placed on veterinarian's list for 60 days, must pass commission-approved examination before being eligible to run

*If the trainer has not had more than one violation within the previous two years, the Stewards/Judges are encouraged to issue a warning in lieu of a fine provided the reported level is below 3.0 mcg/ml absent of aggravating factors.

After a two-year period, if the licensee has had no further violations, any penalty due to an overage in the 2.0-5.0 category will be expunged from the licensee's record for penalty purposes.

Recommended Penalty and Model Rule (Continued)

The recommended penalty for a violation involving a drug that carries a Category "D" penalty is a written warning to the trainer and owner. Multiple violations may result in fines and/or suspension.

Recent Document Revisions

Version	Date	Drug Substance	Notes	Approx. Page(s)
13.00	January 11, 2017		Version 13.00 Publication Date	All
13.00	December 2016	Methdilazine	Changed from Class 4 to Class 3	7, 20
13.00	December 2016	Naepaine	Changed from Class 4/Penalty C to Class 2/Penalty A	8, 16
13.00	December 2016	Nortestosterone	Changed from Class 4/Penalty C to Class 3/Penalty B	8, 32
13.00	December 2016	Olsalazine	Changed from Class 4/Penalty B to Class 5/Penalty C	8, 26
13.00	December 2016	Oxaprozin	Changed from Penalty C to Penalty B	8, 24
13.00	December 2016	Pentoxifylline	Changed from Penalty C to Penalty D	8, 24
13.00	December 2016	Terfenadine	Changed from Penalty B to Penalty C	10, 25
13.00	December 2016	Thiosalicylate	Changed from Penalty C to Penalty B	10, 25
13.00	December 2016	Tripolidine	Changed from Class 4 to Class 3	11, 22
13.00	December 2016	Anisindione	Changed from Penalty C to Penalty D	1, 26
13.00	December 2016	Cilostazol	Changed from Class 5/Penalty C to Class 4/Penalty B	3, 23
13.00	December 2016	Cromolyn	Changed from Penalty C to Penalty D	3, 26
13.00	December 2016	Dimethylsulphone (MSM)	Removed from classifications; recommended "do not report"	n/a
13.00	December 2016	Misoprostol	Changed from Penalty C to Penalty D	7, 26
13.00	December 2016	Nedocromil	Changed from Penalty C to Penalty D	8, 26
13.00	December 2016	Phenindione	Changed from Penalty C to Penalty D	9, 26
13.00	December 2016	Phenprocoumon	Changed from Penalty C to Penalty D	9, 26
13.00	December 2016	Polyethylene Glycol	Changed from Penalty C to Penalty D	9, 26
13.00	December 2016	Warfarin	Changed from Penalty C to Penalty D	11, 26
13.00	December 2016	Pirbuterol	Changed from Penalty A to Penalty B	9, 21
13.00	December 2016	Piroxicam	Changed from Class 3 to Class 4	9, 24
13.00	December 2016	Prostanazol	Changed from Penalty B to Penalty A	9, 21
13.00	December 2016	Quinbolone	Changed from Penalty B to Penalty A	9, 21
13.00	December 2016	Scopolamine	Changed from Class 3/Penalty B to Class 4/Penalty C	10, 25
13.00	December 2016	Stenbolone	Changed from Penalty B to Penalty A	10, 22
13.00	December 2016	TCO ₂	Changed from Unclassified with Penalty B recommended to Class 3/Penalty B	10, 22
13.00	December 2016	Acetazolamide	Changed from Penalty B to Penalty C	1, 23
13.00	December 2016	Ambroxol	Changed from Penalty C to Penalty B	1, 23

Version	Date	Drug Substance	Notes	Approx. Pages
13.00	December 2016	Brompheniramine	Changed from Class 4 to Class 3	2, 19
13.00	December 2016	Butacaine	Changed from Class 4/Penalty C to Class 2/Penalty A	2, 14
13.00	December 2016	Carbazochrome	Changed from Penalty C to Penalty B	2, 23
13.00	December 2016	Ciclesonide	Changed from Penalty B to Penalty C	3, 23
13.00	December 2016	Cinchocaine	Changed from Class 4/Penalty C to Class 2/Penalty A	3,4,14, 15
13.00	December 2016	Clibucaine	Changed from Class 4/Penalty C to Class 2/Penalty A	3,15
13.00	December 2016	Clormecaine	Changed from Class 4/Penalty C to Class 2/Penalty A	3,15
13.00	December 2016	Cyclizine	Changed from Class 4 to Class 3	3,19
13.00	December 2016	Cyproheptadine	Changed from Class 4/Penalty C to Class 3/Penalty B	3,19
13.00	December 2016	Dibucaine	Changed from Class 4/Penalty C to Class 2/Penalty B	4,15
13.00	December 2016	Eltenac	Changed from Penalty C to Penalty B	4,23
13.00	December 2016	Ethoheptazine	Changed from Class 4/Penalty C to Class 2/Penalty A	4,15
13.00	December 2016	Fluorometholone	Changed from Penalty B to Penalty C	5,24
13.00	December 2016	Fluoroprednisolone	Changed from Penalty C to Penalty B	5,24
13.00	December 2016	Hexylcaine	Changed from Class 4/Penalty C to Class 2/Penalty B	5,16
13.00	December 2016	Isoxsuprine	Changed from Penalty C to Penalty D	6,24
13.00	December 2016	Letosteine	Changed from Penalty C to Penalty B	6,24
13.00	December 2016	Loratidine	Changed from Penalty B to Penalty C	6,24
13.00	December 2016	Meclizine	Changed from Class 4 to Class 3	6,20
13.00	December 2016	Methapyrilene	Changed from Class 4 to Class 3	7,20
13.00	December 2016	Amyl Nitrite	Changed from Class 3 to Class 2	1,14
13.00	December 2016	Arformoterol	Changed from Penalty A to Penalty B	1,19
13.00	December 2016	Calusterone	Changed from Penalty B to Penalty A	2,19
13.00	December 2016	Clostebol	Changed from Penalty B to Penalty A	3,19
13.00	December 2016	Dehydrochloromethyltestosterone	Changed from Penalty B to Penalty A	3,19
13.00	December 2016	Desoxymethyltestosterone	Changed from Penalty B to Penalty A	3,19
13.00	December 2016	Enalapril	Changed from Penalty B to Penalty A	4,20
13.00	December 2016	Felbamate	Changed from Penalty A to Penalty B	5,20
13.00	December 2016	Furazabol	Changed from Penalty B to Penalty A	5,20
13.00	December 2016	Glycopyrrolate	Changed from Class 3/Penalty B to Class 4/Penalty C	5,24
13.00	December 2016	Mepenzolate	Changed from Penalty A to Penalty B	6,20

Version	Date	Drug Substance	Notes	Approx. Page(s)
13.00	December 2016	Mestanolone	Changed from Penalty B to Penalty A	7,20
13.00	December 2016	Mesterolone	Changed from Penalty B to Penalty A	7,20
13.00	December 2016	Methandrostenolone (Methandienone)	Added alternate name, Changed from Penalty B to Penalty A	7,20
13.00	December 2016	Methandriol (Methylandrostenediol)	Added alternate name, Changed from Penalty B to Penalty A	7,20
13.00	December 2016	Metenolone	Changed from Penalty B to Penalty A	7,20
13.00	December 2016	Methyldienolone	Changed from Penalty B to Penalty A	7,21
13.00	December 2016	Methylnoretestosterone (Trestolone)	Added alternate name, Changed from Penalty B to Penalty A	7,21
13.00	December 2016	Methsuximide	Changed from Class 3/Penalty A to Class 4/Penalty B	7,24
13.00	December 2016	Methyltestosterone	Changed from Penalty B to Penalty A	7,21
13.00	December 2016	Naloxone	Changed from Penalty A to Penalty B	8,21
13.00	December 2016	Naltrexone	Changed from Penalty A to Penalty B	8,21
13.00	December 2016	N-Butylscopolamine	Changed from Class 3/Penalty B to Class 4/Penalty C	2,7,24
13.00	December 2016	Nitroglycerin	Changed from Class 3 to Class 2	8,16
13.00	December 2016	Norbolethone/Norboletoleone	Added alternate spelling, Changed from Penalty B to Penalty A	8,21
13.00	December 2016	Norclostebol	Changed from Penalty B to Penalty A	8,21
13.00	December 2016	Oxabolone	Changed from Penalty B to Penalty A	8,21
13.00	December 2016	Oxprenolol	Changed from Penalty B to Penalty A	8,21
13.00	December 2016	Physostigmine	Changed from Penalty B to Penalty A	9,21
13.00	December 2016	Pindolol	Changed from Penalty A to Penalty B	9,21
13.00	December 2016	Amitraz	Changed from Penalty A to Penalty B	1,19
13.00	December 2016	Alprenolol	Changed from Class 3 to Class 2	1,14
13.00	December 2016	Zomepirac	Changed from Penalty A to Penalty B	11,18
13.00	December 2016	Yohimbine	Changed from Penalty A to Penalty B	11,18
13.00	December 2016	Snake Venoms	Changed from Class 2 to Class 1	10,13
13.00	December 2016	Romifidine	Changed from Class 2 to Class 3	10,21
13.00	December 2016	Rofecoxib	Changed from Penalty A to Penalty B	10,17
13.00	December 2016	Reserpine	Changed from Penalty A to Penalty B	10,17
13.00	December 2016	Midazolam	Changed from Class 2/Penalty A to Class 3/Penalty B	7,21
13.00	December 2016	Loperamide	Changed from Class 2/Penalty A to Class 3/Penalty B	6,20
13.00	December 2016	Isoxicam	Changed from Penalty A to Penalty B	6,16
13.00	December 2016	Fluphenazine	Changed from Penalty A to Penalty B	5,15
13.00	December 2016	Fenclozic Acid	Changed from Penalty A to Penalty B	5,15

Version	Date	Drug Substance	Notes	Approx. Page(s)
13.00	December 2016	Erythropoietin	Changed from Class 2 to Class 1	4, 12
13.00	December 2016	Diazepam	Changed from Class 2 to Class 3	4, 19
13.00	December 2016	Darbepoetin	Changed from Class 2 to Class 1; Corrected spelling under "Prohibited Practices"	vi, 3, 12
13.00	December 2016	Chlorpromazine	Changed from Class 2 to Class 1	3, 12
13.00	December 2016	Benoxaprofen	Changed from Penalty A to Penalty B	1, 14
13.00	December 2016	Alclofenac	Changed from Penalty A to Penalty B	1, 14
13.00	December 2016	Atipamazole	Added to Uniform Classification Guide as Class 2, Penalty B	1, 14
13.00	December 2016	Cocaine	Changed from Penalty B to Penalty A	3, 12
13.00	December 2016	Ethylphenidate	Added to Uniform Classification Guide as Class 1, Penalty A	5, 12
13.00	December 2016	Meldonium	Added to Uniform Classification Guide as Class 1, Penalty A	6, 12
13.00	December 2016	Morphine	Changed from Penalty B to Penalty A	7, 12
13.00	December 2016	Strychnine	Changed from Penalty B to Penalty A	10, 13
12.00	March 2016	Methamphetamine	Added footnote language recommending Penalty B if testing can prove presence of only levo-methamphetamine is present in sample.	7, 13
12.00	March 2016	Tramadol	Changed from Penalty A to Penalty B	11, 19
12.00	March 2016	Cetirizine	Changed from Penalty B to Penalty C after inclusion into ARCI Controlled Therapeutic Medication Schedule	2, 24
12.00	March 2016	Morphine	Added footnote language recommending Penalty A if intentional administration can be proven by regulators.	8, 13
12.00	March 2016	Cocaine	Added footnote language recommending Penalty A if intentional administration can be proven by regulators.	3, 13
12.00	March 2016	Methacholine	Corrected spelling error in Alphabetical Listing by Substance Section and Listing by Classification Section	7, 20
12.00	March 2016	myo-inositol trispyrophosphate (ITPP)	Corrected spelling error in Alphabetical Listing by Substance Section and Listing by Classification Section	8, 13
11.00	December 2015	2-Aminoheptane	Corrected typographical error to reflect Class 4, Penalty B Substance	1, 23
11.00	December 2015	Xylometazoline	Corrected typographical error to reflect Class 4, Penalty B Substance	11, 25
11.00	December 2015	Rivastigmine	Corrected typographical error to reflect Class 2, Penalty A Substance	10, 17

Version	Date	Drug Substance	Notes	Approv. Page(s)
11.00	December 2015	Rabeprazole	Corrected typographical error to reflect Class 5, Penalty D Substance	10, 26
11.00	December 2015	Prilocaine	Corrected typographical error to reflect Class 2, Penalty A Substance	9, 17
11.00	December 2015	Hexocyclium	Corrected typographical error to reflect Class 4, Penalty B Substance	6, 24
11.00	December 2015	Gabapentin	Corrected typographical error to reflect Class 3, Penalty B Substance	5, 20
11.00	December 2015	Ergoloid Mesylates	Corrected typographical error to reflect Class 2, Penalty A Substance	4, 15
11.00	December 2015	Butacaine	Corrected typographical error to reflect Class 4, Penalty B Substance	2, 23
11.00	December 2015	Budesonide	Corrected typographical error to reflect Class 4, Penalty C Substance	2, 23
11.00	December 2015	Brimonidine	Corrected typographical error to reflect Class 2, Penalty A Substance	2, 14
11.00	December 2015	Benazepril	Corrected typographical error to reflect Class 3, Penalty B Substance	2, 19
11.00	December 2015	Amlodipine	Corrected typographical error to reflect Class 3, Penalty B Substance	1, 19
11.00	December 2015	3-Methoxytyramine	Added as Class 2, Penalty A Substance	1, 14
10.00	July 2015	Methylhexanamine	Added alternative spelling	7, 13
10.00	July 2015	Gamma Aminobutyric Acid (GABA)	Added as Class 3, Penalty B Substance	5, 19
9.00	April 2015	Cobalt	Added as Class 3, Penalty B with note to refer to ARCI Endogenous, Dietary, or Environmental Substances Schedule for threshold and penalty information for contractions of less than 50 parts per billion (ppb) in blood serum or plasma	3, 18
8.00	December 2014	Firocoxib	Changed Penalty Class from "B" to "C" to conform to the ARCI Controlled Therapeutic Medication Schedule	5, 23
8.00	December 2014	Acenocoumarol	Had been previously omitted from Listing by Classification Section, Added to section	25

Version	Date	Drug Substance	Notes	Approv. Page(s)
8.00	December 2014	Deracoxib	Corrected Spelling in Alphabetical Listing by Substance Section	3
8.00	December 2014	Norclostebol	Corrected Spelling in Alphabetical Listing by Substance Section	8
8.00	December 2014	Rizatriptan	Corrected Spelling in Alphabetical Listing by Substance Section	10
8.00	December 2014	Dehydrochloromethyltestosterone	Corrected Spelling in Alphabetical Listing by Substance Section	3
8.00	December 2014	Amiodarone	Corrected Spelling in Listing by Classification Section	22
8.00	December 2014	2-Aminoheptane	Corrected Spelling in Listing by Classification Section	22
8.00	December 2014	Bupropion	Corrected Spelling in Listing by Classification Section	13
8.00	December 2014	Alclofenac	Assigned Penalty Class A	1, 13
8.00	December 2014	Recommended Penalties for Ketoprofen	Updated the recommended penalty for Ketoprofen to comply with the primary threshold established in the ARCI Controlled Therapeutic Medication Schedule.	29
8.00	December 2014	Class B Recommended Penalties	Corrected typographical error on recommended penalties for Class B substances for licensed owners. Version 7.00 incorrectly recommended penalties for second or third offense in the owner's lifetime. Version 8.00 corrects error and recommends penalty for second or third offense in 365-day period.	28
8.00	December 2014	Aminorex	Addition is not a change of the Uniform Classification Guidelines. Aminorex has been a DEA Schedule I substance. All DEA Schedule I substances are considered Class 1, Penalty A substances by reference. By request, Aminorex has been listed to avoid confusion.	1, 13
8.00	December 2014	Bufotenine	Corrected the precursor to 5-methoxy-N-N dimethyltryptamine	26
7.00	January 2014	Pergolide	Added as Class 3, Penalty B	8, 20
6.00	December 2013	Methylhexanamine	Added as Class 1, Penalty A	7, 12
5.00	December 2012	Zilpatetrol hydrochloride	Moved from Class 3 to Class 2 Substance, Penalty Remains Unchanged	11, 17
5.00	December 2012	Tetramisole hydrochloride	Removed from Non-Classified Substance list	26
5.00	December 2012	Ambroxol	Moved from Class 4, Penalty B to Class 4, Penalty C	1, 22
4.01	October 2012	Ractopamine	Corrected typographical error in Drug Class (Incorrectly listed as a Class 3 substance)	9, 16
4.01	October 2012	Pyrilamine	Corrected typographical error on Penalty Class (Listed as Penalty Class A in "Listing by Classification" section.	9, 20

Version	Date	Drug Substance	Notes	Approx. Page(s)
4.00	July 2012	myo-inositol trispyrophosphate (ITPP)	Added as Class 1, Penalty A	7, 12
4.00	July 2012	Benzonate	Added as Class 2, Penalty A	2, 13
3.00	December 2011	Almotriptan	Corrected Penalty Class omission in Alphabetical Listing section of document	1, 18
3.00	December 2011	Naltrexone	Corrected Penalty Class omission in Alphabetical Listing section of document	7, 20
3.00	December 2011	Amiloride	Corrected Penalty Class omission in Alphabetical Listing section of document	1, 22
3.00	December 2011	Butanilcaine	Corrected Penalty Class omission in Alphabetical Listing section of document	2, 13
3.00	December 2011	3,4-methylenedioxy-pyrovallone, aka MDPV, "Bath Salts"	Corrected typographical error in Trade Name sections	1, 12
3.00	December 2011	Carbazochrome	Added as Class 4, Penalty C	2, 22
2.01	August 2011	Dimethylsulfoxide (DMSO)	Edited Drug Classification definitions to remove mention of DMSO from Class 5 definition	vii
2.00	July 2011	<<Drugs Not Listed>>	Language pertaining to all drugs/substances not found in this document shall be considered a Class I, Penalty A Substance	ii
2.00	July 2011	Phenylbutazone	Penalties for tests over 2.0 micrograms per milliliter of plasma or serum but less than 5.0 micrograms per milliliter of plasma or serum added.	29
2.00	July 2011	Dermorphin	Added as Class 1, Penalty A	3, 12
2.00	July 2011	3,4-methylenedioxy-pyrovallone, aka MDPV, "Bath Salts"	Added as Class 1, Penalty A	1, 12
2.00	July 2011	Synthetic cannabis	Added as Class 1, Penalty A	10, 12
2.00	July 2011	Alclomethasone	Corrected typographical error in spelling	1, 22
1.01	January 2011	Methocarbamol	Corrected typographical error on Penalty Class from Class B to Class C	7, 23
1.00	December 2010	Zilpaterol	Added as Class 3, Penalty a	11, 17

Version	Date	Drug Substance	Notes	Approx. Page(s)
1.00	December 2010	Dimethylsulfoxide (DMSO)	Changed from Class 5 to Class 4	4, 23

ARCI Controlled Therapeutic Medication Schedule for Horses - Version 3.2

Revised – December 9, 2016.

Controlled Therapeutic Medication	Threshold	Withdrawal Guideline	Dosing Specifications	Reference Notes	Note
Acepromazine	10 nanograms per milliliter as 2-(1-hydroxyethyl) promazine sulfoxide (HEPS) in urine	48 hours	Single intravenous dose of acepromazine at 0.05 milligrams per kilogram	University of California at Davis project	Applicable analyte is metabolite HEPS
Albuterol	1 nanogram per milliliter of urine	72 hours	720 micrograms total dose intra-nasal only ¹ . Based upon dosing up to 4 times per day	European Horseracing Scientific Liaison Committee Data	See Endnote
Betamethasone	10 picograms per milliliter of plasma or serum	7 days	Intra-articular administration of 9 milligrams of Betamethasone Sodium Phosphate and Betamethasone Acetate Injectable Suspension, USP (American Regent product #0517-0720-01) ²	RMTC study	Intra-articular dosing only - applicable analyte is betamethasone in plasma or serum
Butorphanol	300 nanograms per milliliter of total butorphanol in urine or 2 nanograms of free butorphanol per milliliter of plasma or serum	48 hours	Single intravenous dose of butorphanol as Torbugesic [®] (butorphanol tartrate) at 0.1 milligrams per kilogram	<i>Journal of Veterinary Pharmacology and Therapeutics</i> doi: 10.1111/j.1365-2885.2012.01385.x	Applicable analytes are total butorphanol (drug and conjugates) in urine and butorphanol in plasma (the drug itself, not any conjugate)

¹ Administration of albuterol by any means other than intra-nasally has a high likelihood in resulting in a positive finding. This specifically includes oral administration. Trainers and veterinarians are cautioned against using oral albuterol

² Intramuscular administration of betamethasone acetate will result in plasma or serum concentrations that will exceed the Regulatory Threshold for weeks or even months, making the horse ineligible to race for an extended period.

Controlled Therapeutic Medication	Threshold	Withdrawal Guideline	Dosing Specifications	Reference Notes	Note
Cetirizine	6 nanograms per milliliter of plasma or serum	48 hours	0.4 milligrams per kilogram twice daily for 5 doses	Kentucky Equine Drug Research Council/University of California at Davis study	Do not administer ivermectin within 48 hours of a race if the horse has been administered cetirizine.
Cimetidine	400 nanograms per milliliter of plasma or serum	24 hours	20 milligrams per kilogram twice daily for 7 doses	Kentucky Equine Drug Research Council/University of California at Davis study	
Clenbuterol	140 picograms per milliliter of urine or Level of Detection in plasma or serum	14 days	Oral administration of clenbuterol as Ventipulmin [®] syrup (Boehringer-Ingelheim Vetmedica Inc., NADA 140-973) at 0.8 mcg/kg twice a day	University of California at Davis; Boehringer-Ingelheim Vetmedica, Inc.	Applicable analyte is clenbuterol
Dantrolene	100 picograms per milliliter of 5-hydroxydantrolene in plasma or serum	48 hours	Oral administration of 500 milligrams of dantrolene as paste (compounding pharmacy) or capsule formulation (Proctor and Gamble)	<i>Journal of Veterinary Pharmacology and Therapeutics</i> 34, 238-246	
Detomidine	2 nanograms per milliliter of carboxydetomidine in urine or 1 nanogram per milliliter of detomidine in blood.	48 hours	5 mg IV (once)	KY EDRC, UC Davis/UF Study.	Dormosedan [™] used in study.

Controlled Therapeutic Medication	Threshold	Withdrawal Guideline	Dosing Specifications	Reference Notes	Note
Dexamethasone	5 picograms per milliliter of plasma or serum	72 hours	Intramuscular and intravenous administration of dexamethasone sodium phosphate or oral administration of dexamethasone at 0.05 milligrams per kilogram regardless of route	RMTC study	Applicable analyte is dexamethasone in plasma or serum
Diclofenac	5 nanograms per milliliter of plasma or serum	48 hours	Five inch ribbon topical application of 1% diclofenac liposomal cream formulation. (Surpass Topical Anti-Inflammatory Cream, IDEXX Pharmaceuticals)	<i>Veterinary Therapeutics</i> 6: 57-66 (2005)	Applicable analyte is diclofenac in plasma or serum
Dimethyl sulfoxide (DMSO)	10 micrograms per milliliter of plasma or serum	48 hours	Intravenous	ARCI model rule	Applicable analyte is DMSO in plasma or serum
Firocoxib	20 nanograms per milliliter of plasma or serum	14 days	Oral administration of firocoxib as EQUIOXX oral paste at a daily dose of 0.1 milligram per kilogram for four days	RMTC study	Applicable analyte is firocoxib in plasma or serum

Controlled Therapeutic Medication		Threshold	Withdrawal Guideline	Dosing Specifications	Reference Notes	Note
Furosemide	100 nanogram per milliliter of plasma or serum	4 hours	Single Intravenous dose of furosemide up to 500 milligram ³	ARCI model rule	Must also have urine specific gravity < 1.010 for a violation.	
Glycopyrrolate	3 picograms per milliliter plasma or serum	48 hours	Single intravenous dose of 1 milligram of glycopyrrolate as Glycopyrrolate Injection, USP (American Regent product # 0517-4601-25)	RMTC study; <i>Journal of Veterinary Pharmacology and Therapeutics</i> doi: 10.1111/j.1365-2885.2011.01272.x	Applicable analyte is glycopyrrolate in plasma or serum	
Guaifenesin	12 nanograms per milliliter of plasma or serum	48 hours	2 grams twice daily for 5 doses	Kentucky Equine Drug Research Council/University of California at Davis study		
Isoflupredone	100 picograms per milliliter of plasma or serum	7 days	10 milligrams total dose subcutaneous or 20 milligrams total dose in one articular space	RMTC Study		
Lidocaine	20 picograms per milliliter of total 30HI-lidocaine in plasma or serum	72 hours	200 milligrams of lidocaine as its hydrochloride salt administered subcutaneously	European Horseracing Scientific Liaison Committee data; Iowa State University study.	Applies to total major hydroxylated metabolite (i.e., includes conjugates)	

³ ARCI-011-020(F)(2)(d) and ARCI-025-020(F)(2)(d) state that the dose of Furosemide “shall not exceed 500 milligrams nor be less than 150 milligrams”.

Controlled Therapeutic Medication	Threshold	Withdrawal Guideline	Dosing Specifications	Reference Notes	Note
Mepivacaine	10 nanograms total hydroxymepivacaine per milliliter of urine or above Level of Detection of mepivacaine in plasma or serum	72 hours	Single 0.07 milligrams per kilogram subcutaneous dose of mepivacaine	European Horseracing Scientific Liaison Committee data	
Methocarbamol	1 nanogram per milliliter of plasma or serum	48 hours	Single intravenous dose of 15 milligrams per kilogram methocarbamol as Robaxin® or 5 grams orally	<i>Journal of Veterinary Pharmacology and Therapeutics</i> doi: 10.1111/jvp.12068	Applicable analyte is methocarbamol in plasma or serum
Methylprednisolone	100 picograms per milliliter of plasma or serum	See Dosing Specifications	Total dose of methylprednisolone acetate suspension in one articular space. ⁴ The recommended withdrawal for methylprednisolone acetate is a minimum of 21 days at a 100 milligram dose	<i>Journal of Veterinary Pharmacology and Therapeutics</i> volume 37, Issue 2, pages 125–132, April 2014	Applicable analyte is methylprednisolone
Omeprazole	omeprazole sulfide - 10 nanograms per milliliter of plasma or serum	24 hours	Orally (2.2 grams) once daily for 4 doses	Kentucky Equine Drug Research Council/University of California at Davis study	GastroGuard™ used in the study

⁴ Intramuscular administration of methylprednisolone acetate will result in plasma or serum concentrations that will exceed the Regulatory Threshold for weeks or even months, making the horse ineligible to race for an extended period. Please see Dosing Specifications for recommended withdrawal time.

Controlled Therapeutic Medication	Threshold	Withdrawal Guideline	Dosing Specifications	Reference Notes	Note
Prednisolone	1 nanogram per milliliter of plasma or serum	48 hours	1 milligram per kilogram orally		Applicable analyte is prednisolone in plasma or serum
Procaine penicillin (administration must be reported to Commission)	25 nanograms per milliliter of plasma or serum	Following entry to race	Intramuscular	RMTC – reference notes online	Mandatory surveillance of horse at owner's expense 6 hours before racing
Ranitidine	40 nanograms per milliliter of plasma or serum	24 hours	8 milligrams per kilogram twice daily for 7 doses	Kentucky Equine Drug Research Council/University of California at Davis study	
Triamcinolone acetonide	100 picograms per milliliter of plasma or serum	7 days	Total dose of 9 milligram in one articular space ⁵	<i>Equine Veterinary Journal</i> , 10.1111/evj.12059 (2013)	Applicable analyte is triamcinolone acetonide in plasma or serum
Xylazine	200 picograms per milliliter of plasma or serum	48 hours	200 milligrams intravenously	University of California at Davis study	Applicable analyte is xylazine.

⁵ Intramuscular administration of triamcinolone acetonide will result in plasma or serum concentrations that will exceed the Regulatory Threshold for weeks or even months, making the horse ineligible to race for an extended period.

Non-Steroidal Anti-Inflammatory Drug (NSAID) Rules for Horses^{††}

Controlled Therapeutic Medication	Threshold (Primary)	Withdrawal Guideline	Dosing Specifications	Reference Notes	Threshold (Secondary)
Flunixin	20 nanogram per milliliter of plasma or serum	32 hours	Single intravenous dose of flunixin as Banamine® (flunixin meglumine) at 1.1 milligram per kilogram	University of California at Davis/RMTC study	Secondary anti-stacking threshold: 3.0 nanograms per milliliter of plasma or serum (Administration 48 hours prior)
Ketoprofen	2 nanograms per milliliter of plasma or serum	24 hours	Single intravenous dose of ketoprofen as Ketofen® at 2.2 milligrams per kilogram	HFL Sport Sciences/ Kentucky Equine Drug and Research Council/RMTC study	Secondary anti-stacking threshold: <u>1 nanogram per milliliter of plasma or serum (Administration 48 hours prior)</u>
Phenylbutazone	2 micrograms per milliliter of plasma or serum	24 hours	Single intravenous dose of phenylbutazone at 4.0 milligrams per kilogram	ARCI model rule	Secondary anti-stacking threshold: 0.3 micrograms per milliliter of plasma or serum (Administration 48-hours prior)

^{††} Samples collected may contain one of the NSAIDs in this chart at a concentration up to the Primary Threshold. Samples may also contain another of the NSAIDs in this chart up to a concentration up to the Secondary Threshold. No more than 2 of the NSAIDs in this chart may be present in any sample.

Recent Document Revisions

Date	Version	Revision	Revision Description
Dec-16	3.2	Omeprazole	Clarified threshold for omeprazole sulfide.
Sep-16	3.1	Detomidine	Amended threshold and dosing specifications.
Mar-16	3	Omeprazole	Amended threshold and dosing specifications
Mar-16	3	Xylazine	Amended threshold and dosing specifications
Mar-16	3	Guaifenesin	Added as New Substance to Controlled Therapeutic Medication Schedule
Mar-16	3	Cetirizine	Added as New Substance to Controlled Therapeutic Medication Schedule
Mar-16	3	Ranitidine	Added as New Substance to Controlled Therapeutic Medication Schedule
Mar-16	3	Cimetidine	Added as New Substance to Controlled Therapeutic Medication Schedule
Apr-15	2.02	Methylprednisolone	Directed readers to use Dosing Specification column for recommended withdrawal guideline.
Apr-15	2.02	Furosemide	Added clarifying language to Furosemide reflecting ARCI-011 - 020(F)(2)(d) and ARCI-025-020(F)(2)(d) minimum and maximum thresholds
Apr-15	2.02	Added "For Horses" to Title	Added the words "for Horses" to document title
Apr-14	2.01	Methocarbamol	Corrected dosage from 0.15 milligrams per kilogram to 15 milligrams per kilogram
Apr-14	2	Dimethyl sulfoxide (DMSO)	Removed "oral" from dosing specifications
Apr-14	2	Xylazine	Changed Note section from "Applies to xylazine and xylazine metabolite" to "Applies to analyte xylazine"

Apr-14	2	Xylazine	Corrected typographical error in Threshold from "0.01ng/mg of plasma or serum" to "0.01 nanogram per milliliter of plasma or serum"
Apr-14	2	Isoflupredone	Added Isoflupredone as New Substance to Controlled Therapeutic Medication Schedule
Apr-14	2	Albuterol	Added Albuterol as New Substance to Controlled Therapeutic Medication Schedule
Apr-14	2	Flunixin, Ketoprofen, Phenylbutazone	Added Secondary Anti-Stacking Threshold
Apr-14	2	Flunixin, Ketoprofen, Phenylbutazone	Created separate section for Non-Steroidal Anti-Inflammatory Drugs at end of Controlled Therapeutic Medication Schedule, Relocated Flunixin, Ketoprofen, and Phenylbutazone to new section
Apr-14	2	<All Substances>	Changed Table Header from "No Pre-Race Treatment Within" to "Withdrawal Guideline"
Apr-13	1	<All Substances>	Original Controlled Therapeutic Medication Schedule Adopted by ARCI Board of Directors

